Ubs Group Ag Dermata Therapeutics, Inc. Transaction History

Ubs Group Ag

  • $397 Billion
  • Q1 2024

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 08, 2023
BUY
$0.18 - $0.74 $4,051 - $16,657
22,510 Added 152.12%
37,308 $15,000
Q3 2022

Nov 10, 2022
BUY
$0.1 - $0.76 $359 - $2,729
3,591 Added 32.04%
14,798 $8,000
Q2 2022

Aug 10, 2022
BUY
N/A
6,884 Added 159.24%
11,207 $7,000
Q1 2022

May 16, 2022
BUY
N/A
4,323 New
4,323 $5,000
Q4 2021

Feb 14, 2022
SELL
N/A
-189 Closed
0 $0
Q3 2021

Nov 15, 2021
BUY
N/A
189 New
189 $1,000

Others Institutions Holding DRMA

# of Institutions
1
Shares Held
0
Call Options Held
0
Put Options Held
0
View Full List

About Dermata Therapeutics, Inc.

DRMA Quotes by TradingView
  • Ticker DRMA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 10,102,200
  • Market Cap $24.1M
  • Description
  • Dermata Therapeutics, Inc., a clinical-stage biotechnology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe ...
More about DRMA
Track This Portfolio

Track Ubs Group Ag Portfolio

Follow Ubs Group Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email